Associations of Hospital and Patient Characteristics with Fluid Resuscitation Volumes in Patients with Severe Sepsis: Post Hoc Analyses of Data from a Multicentre Randomised Clinical Trial

PLoS One. 2016 May 19;11(5):e0155767. doi: 10.1371/journal.pone.0155767. eCollection 2016.

Abstract

Purpose: Fluid resuscitation is a key intervention in patients with sepsis and circulatory impairment. The recommendations for continued fluid therapy in sepsis are vague, which may result in differences in clinical practice. We aimed to evaluate associations between hospital and patient characteristics and fluid resuscitation volumes in ICU patients with severe sepsis.

Methods: We explored the 6S trial database of ICU patients with severe sepsis needing fluid resuscitation randomised to hydroxyethyl starch 130/0.42 vs. Ringer's acetate. Our primary outcome measure was fluid resuscitation volume and secondary outcome total fluid input administered from 24 hours before randomisation until the end of day 3 post-randomisation. We performed multivariate analyses with hospital and patient baseline characteristics as covariates to assess associations with fluid volumes given.

Results: We included 654 patients who were in the ICU for 3 days and had fluid volumes available. Individual trial sites administered significantly different volumes of fluid resuscitation and total fluid input after adjusting for baseline variables (P<0.001). Increased lactate, higher cardiovascular and renal SOFA subscores, lower respiratory SOFA subscore and surgery were all independently associated with increased fluid resuscitation volumes.

Conclusions: Hospital characteristics adjusted for patient baseline values were associated with differences in fluid resuscitation volumes given in the first 3 days of severe sepsis. The data indicate variations in clinical practice not explained by patient characteristics emphasizing the need for RCTs assessing fluid resuscitation volumes fluid in patients with sepsis.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Critical Care / methods
  • Female
  • Fluid Therapy / methods*
  • Hospitalization
  • Hospitals
  • Humans
  • Hydroxyethyl Starch Derivatives / therapeutic use*
  • Intensive Care Units
  • Isotonic Solutions / therapeutic use*
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Resuscitation / methods*
  • Sepsis / therapy*

Substances

  • Hydroxyethyl Starch Derivatives
  • Isotonic Solutions
  • Ringer's acetate

Grants and funding

The authors received no specific funding for this work. The 6S trial was funded by the Danish Research Councils and B Braun Melsungen delivered trial fluids to all trial sites. Neither the funders nor B Braun had any role in the conduct of the trial or the analyses or reporting of the data.